BioLineRx Ltd. (TLV:BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1.700
-0.100 (-5.56%)
At close: Dec 4, 2025
BioLineRx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 12.74 | 28.94 | 4.8 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | -42.09% | 502.92% | - | - | - | - | Upgrade
|
| Cost of Revenue | 6.28 | 9.26 | 3.69 | - | - | - | Upgrade
|
| Gross Profit | 6.46 | 19.68 | 1.11 | - | - | - | Upgrade
|
| Selling, General & Admin | 8.99 | 29.68 | 31.58 | 11.53 | 5.31 | 4.75 | Upgrade
|
| Research & Development | 7.53 | 9.15 | 12.52 | 17.63 | 19.47 | 18.17 | Upgrade
|
| Operating Expenses | 16.53 | 38.83 | 44.1 | 29.16 | 24.78 | 22.93 | Upgrade
|
| Operating Income | -10.07 | -19.15 | -42.99 | -29.16 | -24.78 | -22.93 | Upgrade
|
| Interest Expense | -5.44 | -9.07 | -2.14 | -1.79 | -0.98 | -1.47 | Upgrade
|
| Interest & Investment Income | 1.45 | 1.82 | 2.01 | 0.69 | 0.28 | 0.24 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.05 | 0.05 | 0.06 | -0.35 | 0.28 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 12.29 | 18.39 | -10.84 | 5.64 | -1.85 | -5.72 | Upgrade
|
| EBT Excluding Unusual Items | -1.72 | -7.97 | -53.91 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Asset Writedown | -1.26 | -1.26 | -6.7 | - | - | - | Upgrade
|
| Pretax Income | -2.98 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Net Income | -2.98 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Net Income to Common | -2.98 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Shares Outstanding (Basic) | 2,127 | 1,198 | 963 | 774 | 663 | 253 | Upgrade
|
| Shares Outstanding (Diluted) | 2,127 | 1,198 | 963 | 774 | 663 | 253 | Upgrade
|
| Shares Change (YoY) | 86.44% | 24.37% | 24.47% | 16.75% | 162.19% | 72.70% | Upgrade
|
| EPS (Basic) | -0.00 | -0.01 | -0.06 | -0.03 | -0.04 | -0.12 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.01 | -0.06 | -0.03 | -0.04 | -0.12 | Upgrade
|
| Free Cash Flow | -13.48 | -43.93 | -22.72 | -26.37 | -23.67 | -23.21 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.04 | -0.02 | -0.03 | -0.04 | -0.09 | Upgrade
|
| Gross Margin | 50.70% | 67.99% | 23.08% | - | - | - | Upgrade
|
| Operating Margin | -79.08% | -66.18% | -895.65% | - | - | - | Upgrade
|
| Profit Margin | -23.38% | -31.86% | -1262.79% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -105.83% | -151.78% | -473.42% | - | - | - | Upgrade
|
| EBITDA | -8.37 | -15.7 | -41.67 | -28.5 | -24.07 | -21.99 | Upgrade
|
| EBITDA Margin | -65.73% | -54.25% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.7 | 3.45 | 1.33 | 0.65 | 0.7 | 0.93 | Upgrade
|
| EBIT | -10.07 | -19.15 | -42.99 | -29.16 | -24.78 | -22.93 | Upgrade
|
| EBIT Margin | -79.08% | -66.18% | - | - | - | - | Upgrade
|
| Revenue as Reported | 12.74 | 28.94 | 4.8 | - | - | - | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.